Literature DB >> 25977228

It is not just IMRT: Human papillomavirus related oropharynx squamous cell carcinoma is associated with better swallowing outcomes after definitive chemoradiotherapy.

M Naik1, M C Ward1, T J Bledsoe2, A M S Kumar1, L A Rybicki3, J P Saxton1, B B Burkey4, J F Greskovich1, D J Adelstein5, S A Koyfman6.   

Abstract

OBJECTIVES: Long term swallowing dysfunction in patients with oropharynx squamous cell carcinoma (OPSCC) treated with concurrent chemoradiation (CRT) is declining. While the use of intensity modulated radiotherapy (IMRT) is commonly believed to be a potential cause, we hypothesize that the increasing incidence of human papillomavirus (HPV) related disease may also favorably impact this outcome.
MATERIALS AND METHODS: We reviewed 130 HPV+ and 17 HPV- patients with stage III-IV OPSCC treated exclusively with conventional 3-field radiotherapy with chemotherapy between 2002 and 2010. The rates of normal diet, limited diet (significant restrictions in the types of foods eaten, and/or requiring nutritional supplementation for weight maintenance) and feeding tube dependence (FTD) were compared between HPV+ and HPV- patients. Cox proportional hazards modeling were used to perform univariate analysis (UVA) to examine predictors of a combined endpoint of dietary limitation, which included limited diet and/or FTD. These outcomes were also compared to our previously reported cohort of OPSCC patients treated between 1989 and 2002 to assess changes in toxicity over time given the changing disease epidemiology, in the setting of identical treatment regimens.
RESULTS: With a median follow-up of 55 months, HPV+ patients more frequently had resumed a normal diet (87% vs. 65%) at last follow up and had lower rates of limited diet (9% vs. 18%) and FTD (4% vs. 18%) compared to HPV- patients (p=0.02). HPV status was the only significant predictor of reduced swallowing dysfunction on UVA (HR 0.19; p=0.008). When compared to our 1989-2002 cohort, patients treated between 2002 and 2010 had less FTD (7.5% vs. 34%, p<0.001) and dietary limitations (26% vs.46%, p<0.001) at 6 months post treatment.
CONCLUSIONS: HPV+ patients with OPSCC have reduced late swallowing dysfunction after chemoradiation compared to HPV- patients. The changing epidemiology of OPSCC may play a role in toxicity reduction in these patients, independent of the increasing use of IMRT.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  3D-conformal radiation; Human-papillomavirus; Late toxicity; Oropharyngeal cancer

Mesh:

Year:  2015        PMID: 25977228     DOI: 10.1016/j.oraloncology.2015.04.008

Source DB:  PubMed          Journal:  Oral Oncol        ISSN: 1368-8375            Impact factor:   5.337


  10 in total

Review 1.  Association of pretreatment body mass index and survival in human papillomavirus positive oropharyngeal squamous cell carcinoma.

Authors:  William G Albergotti; Kara S Davis; Shira Abberbock; Julie E Bauman; James Ohr; David A Clump; Dwight E Heron; Umamaheswar Duvvuri; Seungwon Kim; Jonas T Johnson; Robert L Ferris
Journal:  Oral Oncol       Date:  2016-07-07       Impact factor: 5.337

2.  Commercial Claims-Based Comparison of Survival and Toxic Effects of Definitive Radiotherapy vs Primary Surgery in Patients With Oropharyngeal Squamous Cell Carcinoma.

Authors:  David J Sher; Abiy Agiro; Siting Zhou; Andrew T Day; Andrea DeVries
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2018-10-01       Impact factor: 6.223

Review 3.  The Older Adult With Locoregionally Advanced Head and Neck Squamous Cell Carcinoma: Knowledge Gaps and Future Direction in Assessment and Treatment.

Authors:  Ronald Maggiore; Zachary S Zumsteg; Karlynn BrintzenhofeSzoc; Kelly M Trevino; Ajeet Gajra; Beatriz Korc-Grodzicki; Joel B Epstein; Stewart M Bond; Ira Parker; Julie A Kish; Barbara A Murphy; Noam A VanderWalde
Journal:  Int J Radiat Oncol Biol Phys       Date:  2017-07-15       Impact factor: 7.038

4.  Reduced feeding tube duration with intensity-modulated radiation therapy for head and neck cancer: A Surveillance, Epidemiology, and End Results-Medicare Analysis.

Authors:  Beth M Beadle; Kai-Ping Liao; Sharon H Giordano; Adam S Garden; Katherine A Hutcheson; Stephen Y Lai; B Ashleigh Guadagnolo
Journal:  Cancer       Date:  2016-09-23       Impact factor: 6.860

5.  Predicting two-year longitudinal MD Anderson Dysphagia Inventory outcomes after intensity modulated radiotherapy for locoregionally advanced oropharyngeal carcinoma.

Authors:  Ryan P Goepfert; Jan S Lewin; Martha P Barrow; C David Fuller; Stephen Y Lai; Juhee Song; Brian P Hobbs; G Brandon Gunn; Beth M Beadle; David I Rosenthal; Adam S Garden; Merrill S Kies; Vali A Papadimitrakopoulou; David L Schwartz; Katherine A Hutcheson
Journal:  Laryngoscope       Date:  2016-07-21       Impact factor: 3.325

6.  Comparison of Patient- and Practitioner-Reported Toxic Effects Associated With Chemoradiotherapy for Head and Neck Cancer.

Authors:  Aaron D Falchook; Rebecca Green; Mary E Knowles; Robert J Amdur; William Mendenhall; David N Hayes; Juneko E Grilley-Olson; Jared Weiss; Bryce B Reeve; Sandra A Mitchell; Ethan M Basch; Bhishamjit S Chera
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2016-06-01       Impact factor: 6.223

Review 7.  Time to change perspectives on HPV in oropharyngeal cancer. A systematic review of HPV prevalence per oropharyngeal sub-site the last 3 years.

Authors:  Linnea Haeggblom; Torbjörn Ramqvist; Massimo Tommasino; Tina Dalianis; Anders Näsman
Journal:  Papillomavirus Res       Date:  2017-05-19

8.  Disease-induced and treatment-induced alterations in body composition in locally advanced head and neck squamous cell carcinoma.

Authors:  Anna C H Willemsen; Ann Hoeben; Roy I Lalisang; Ardy Van Helvoort; Frederik W R Wesseling; Frank Hoebers; Laura W J Baijens; Annemie M W J Schols
Journal:  J Cachexia Sarcopenia Muscle       Date:  2019-09-19       Impact factor: 12.910

9.  The PRO-ACTIVE trial protocol: a randomized study comparing the effectiveness of PROphylACTic swallow InterVEntion for patients receiving radiotherapy for head and neck cancer.

Authors:  R Martino; M I Fitch; C D Fuller; A Hope; G Krisciunas; S E Langmore; C Lazarus; C L Macdonald; T McCulloch; G Mills; D A Palma; K Pytynia; J Ringash; K Sultanem; J Theurer; K E Thorpe; K Hutcheson
Journal:  BMC Cancer       Date:  2021-10-13       Impact factor: 4.430

Review 10.  The changing face of head and neck cancer: are patients with human papillomavirus-positive disease at greater nutritional risk? A systematic review.

Authors:  Anna Edwards; Teresa Brown; Brett G M Hughes; Judy Bauer
Journal:  Support Care Cancer       Date:  2022-04-27       Impact factor: 3.359

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.